YB new stock pitches (Wed, May 6)

Pro-Dex (PDEX) is the exclusive supplier of robotic arms, gearing, and blades for Monogram's semi-autonomous knee surgery robot, which is being marketed by Zimmer Biomet (ZBH), a market leader in orthopedic surgery. Zimmer Biomet is deploying approximately 1,000 sales representatives (roughly one-third of their salesforce) to launch this product, a significant commitment given that Pro-Dex's entire headcount is smaller than this deployment. The device has cleared major regulatory hurdles in the highest value market and represents the first demonstration of level 5 autonomy in total knee arthroplasty, offering technological advantages over existing devices by reducing labor requirements. Orthopedic surgeons are responding enthusiastically at product demos, including displays at the 2025 AAHKS Annual meeting in Dallas. Under the supplier agreement, Pro-Dex holds contingent value rights (CVRs) tied to an earnout structure where $1.1 billion in cumulative revenue for Zimmer over three years would result in approximately $20 million payable to Pro-Dex, plus ongoing product sales of disposables and non-disposable robot components. Pro-Dex's legacy business is growing at mid-to-high teens rates while the company expands manufacturing capacity, and the Monogram launch is expected to materially accelerate topline sales growth with higher margins than current products within six months when backlog changes are reported. A typical Zimmer salesperson supports over seven surgeries per week, suggesting significant volume potential. The stock is estimated to trade at less than 3x FY2029 earnings, which appears cheap for a medtech company with an install base supporting recurring sales, with the market mispricing likely due to Pro-Dex's poor communication beyond legally required disclosures. Pro-Dex is hosting their first official PR event in years at Planet Microcap Las Vegas 2026 on June 16-18.

Read the full article here. Read time: 2 min

Veeva Systems (VEEV), a vertical SaaS monopoly in life sciences software, is trading at $158 per share, roughly half its 52-week high of $310, as the market fixates on the company's complex migration from Salesforce infrastructure to its proprietary Vault CRM platform, which must be completed by September 2030. The company generated $3.195 billion in fiscal 2026 revenue (up 16% year-over-year), $1.43 billion in non-GAAP operating income, $1.42 billion in operating cash flow, with zero debt and $6.56 billion in cash on the balance sheet, while operating ROIC has expanded to 92% versus a 9% WACC, creating an extraordinary 83-percentage-point spread. The revenue mix has shifted decisively toward the stickier R&D and Quality Solutions segment, which generated $1.43 billion in subscriptions (up 21% year-over-year), now exceeding the Commercial Solutions segment's $1.26 billion (up 14%), with Vault CRM already live with over 125 customers including two top-20 biopharmas and roughly 14 of the top 20 global pharmas expected to commit by year-end. The company's moat rests on near-insurmountable switching costs in heavily regulated pharma workflows, network effects in clinical operations, and regulatory complexity as a barrier to entry, even against Salesforce's 2024-launched Life Sciences Cloud. A three-scenario DCF analysis yields a base-case intrinsic value of $205 per share (assuming 13% five-year growth, 47% operating margins, and 9% WACC), a bear case of $142 (assuming 8% growth and margin pressure from Salesforce competition), and a bull case of $285 (assuming 17% growth from AI agents and new Vault modules), with a probability-weighted intrinsic value of $205 representing a price-to-value ratio of 0.77x and a comfortable margin of safety. Veeva scores 45 out of 47 on the firm's 40-point ROIC-spread scorecard and lands in Quadrant 1 (wide positive spread trading below intrinsic value), warranting a BUY rating with 7-10% portfolio sizing in long-duration holdings, though risks include Vault CRM migration execution, Salesforce competition, pharma macro pressures from IRA drug pricing reform and biotech funding challenges, and founder concentration risk with CEO Peter Gassner owning 7.5% of shares. For options traders, the firm recommends selling cash-secured puts at the $145 strike (May 30 expiry) for roughly 2.3% absolute yield over 35-40 days, or covered calls at the $185 strike for existing shareholders, with positions to be closed at 21 days to expiration to manage gamma.

Read the full article here. Read time: 9 min

Red Violet (RDVT) operates a proprietary data aggregation platform processing public and proprietary records to build comprehensive identity graphs for fraud prevention, risk mitigation, and investigative work across corporate, financial, and government sectors, sold through its IDI and FOREWARN brands. The company generates approximately 90% usage-based revenue, making it an AI winner rather than loser since AI-driven automation increases queries rather than compressing seats, while the proprietary data infrastructure built over a decade cannot be easily replicated. RDVT delivered 20% revenue growth in 2025 with IDI growing 17.6% and FOREWARN growing 32%, driven by 127 customers spending over $100K annually (up 32% year-over-year) representing 20-25% of revenue, 108% net revenue retention, and 95-96% gross retention. The company has expanded gross margins toward the 85-90% peer benchmark and FCF ex-SBC margins to 13% in 2025 (expanding toward 40-50% peer levels), with 76% of revenue covered by multi-year minimum commitments providing high visibility. With $45 million cash, no debt, active share buybacks ($16.4 million remaining in authorization as of February 2026), and only 7.2% SBC-to-revenue ratio resulting in minimal 1.3% dilution, management has demonstrated capital discipline. The stock trades at 25x EV/NTM EBIT and 30x FCF ex-SBC, which appears mispriced given the company's positioning as competitors like LexisNexis and TransUnion operate on legacy mainframe systems while RDVT's cloud-native, AI-enabled platform built in proprietary IRON language provides competitive advantages. Key risks include potential regulatory changes around data collection, competition from larger scaled players with stronger balance sheets, and supplier concentration with 44% of data from a single vendor (though renewed through 2030 with minimal price increases). The estimated 2029 price target of $60 implies approximately 25% IRR, driven by continued 20% annual revenue growth, margin expansion, minimal dilution through buybacks, and strong unit economics with IDI customer LTV:CAC exceeding 8x.

Read the full article here. Read time: 8 min